Related Experiment Video
Updated: Feb 26, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.7K
[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know]
1Especialista en Medicina Interna, lipidólogo clínico, Facultad Medicina, Universidad FASTA, Departamento Farmacología, Mar del Plata, Buenos Aires, Argentina.
Hipertension Y Riesgo Vascular
|July 16, 2017
Summary
The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) led to new lipid-lowering therapies. Monoclonal antibodies targeting PCSK9 significantly reduce LDL cholesterol, with ongoing research into long-term efficacy and safety.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Familial hypercholesterolemia (HF) research identified proprotein convertase subtilisin/kexin type 9 (PCSK9) in 2003.
- PCSK9 plays a crucial role in cholesterol metabolism and LDL receptor regulation.
Purpose of the Study:
- To review the historical discovery of PCSK9.
- To examine the physiology and pathophysiology of PCSK9.
- To discuss the development and clinical application of PCSK9 inhibitors.
Main Methods:
- Literature review of PCSK9 discovery and development.
- Analysis of clinical trial data for PCSK9 inhibitors.
- Synthesis of current knowledge on PCSK9's role in lipid disorders.
Main Results:
- PCSK9 discovery spurred the development of novel pharmacological strategies.
- Monoclonal antibodies targeting PCSK9, approved 12 years post-discovery, effectively lower LDL-C and other lipid subfractions.
- Significant progress has been made in understanding PCSK9's impact on cardiovascular health.
Conclusions:
- PCSK9 inhibition represents a major advancement in managing hypercholesterolemia.
- Further investigation is needed to fully elucidate the long-term efficacy and safety profile of PCSK9 inhibitors.
- Understanding PCSK9's complex role continues to evolve, offering new therapeutic avenues.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
01:29Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
01:26Atherosclerosis III: Management
512
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
512
01:26Coronary Artery Disease IV: Preventive Measures
770
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
770
01:30Coronary Artery Disease I: Introduction
1.3K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
01:25Pharmacokinetics: Drug–Drug Interactions
539
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
539